LUTS in Men Algorithm · Reasoning GP

1

Safety

Red Flags — Exclude Emergencies & Serious Pathology First

Done

Screen for these before proceeding — each requires urgent action today or 2WW referral.

Acute urinary retention Inability to void, suprapubic pain, distended tender bladder → 999 / A&E catheterisation

Haematuria (painless, visible) Frank haematuria without UTI → 2WW urology (bladder/upper tract malignancy — NICE NG12)

Haematuria + LUTS + age ≥45 Even if infection plausibly present → 2WW urology; treat UTI but still refer

Suspected prostate cancer Hard/irregular DRE, rapidly rising PSA, bone pain, weight loss → 2WW urology

Neurological bladder New saddle anaesthesia, bilateral leg weakness, incontinence/retention post spinal trauma → 999 (cauda equina)

Sepsis / febrile UTI / pyelonephritis Fever, rigors, loin pain, systemically unwell → Same-day assessment or 999 if sepsis criteria met

Elevated creatinine / hydronephrosis Renal impairment on bloods with LUTS → Same-day urology — obstructive uropathy

Testicular or pelvic mass Incidental finding or reported lump on history → 2WW urology (testicular cancer most common cancer 15–35)

Acute retention causes bladder injury if not relieved within hours; trial without catheter (TWOC) can be arranged but acute management is secondary care.
Painless visible haematuria is bladder cancer until proven otherwise — sensitivity of 2WW pathway 85%+ for bladder malignancy (NICE NG12 2015, updated 2023).
Cauda equina is a neurosurgical emergency; 6-hour window for decompression to avoid permanent deficit.
Obstructive uropathy with rising creatinine indicates back-pressure on kidneys — chronic kidney disease and irreversible loss of function without urgent relief.
Missing prostate cancer at a curable stage is a significant medicolegal risk; hard irregular prostate on DRE warrants urgent referral regardless of PSA.

2

Diagnose

Symptom Quantification — IPSS Score & Symptom Classification

Done

Use the International Prostate Symptom Score (IPSS) to quantify severity and guide management threshold — validated in NICE CG97.

IPSS Tool

7 questions, each scored 0–5. Plus 1 quality-of-life (QoL) question (0–6). Total 0–35. Available at NICE CKS or patient-held leaflet

Mild (0–7)

Watchful waiting ± lifestyle advice. Reassess in 6–12 months if no progression

Moderate (8–19)

Active treatment threshold. Offer lifestyle + pharmacotherapy discussion

Severe (20–35)

Significant impact on QoL. Offer treatment; consider urology if refractory or complex

QoL question

Score ≥3 ("mostly dissatisfied" or worse) = significant bother — patient's own perception drives treatment urgency

Bladder diary

3-day voiding diary: frequency, volumes, nocturia episodes, leakage. Distinguishes storage (overactive bladder) from voiding (outflow) symptoms. Send diary home

Symptom types

Storage: urgency, frequency, nocturia, urge incontinence
Voiding: hesitancy, poor stream, straining, incomplete emptying
Post-micturition: dribble, sensation of incomplete emptying

The IPSS is the internationally validated primary care tool endorsed by NICE CG97 and EAU guidelines; it allows objective tracking of symptom progression and treatment response.
Distinguishing storage from voiding symptoms matters: storage symptoms may be OAB (responds to anticholinergics/beta-3 agonists) rather than BPH outflow obstruction (responds to alpha-blockers/5-ARIs). Treating the wrong phenotype causes harm.
A 3-day bladder diary detects nocturnal polyuria (urine output >33% nocturnal) — which needs desmopressin, not BPH treatment — avoiding unnecessary alpha-blocker prescription.
Patient QoL score is a better driver of treatment decision than IPSS alone — a man with IPSS 10 but QoL 5 deserves active treatment as much as IPSS 20.

3

Diagnose

Differential Diagnosis — Classify the Underlying Cause

Done

LUTS in men is not synonymous with BPH — consider the full differential for each symptom cluster.

Benign Prostatic Hyperplasia (BPH)

Most common cause in men >50. Voiding + storage symptoms. Enlarged smooth prostate on DRE. Gradual onset. Normal PSA for age or mildly elevated

Overactive Bladder (OAB)

Predominantly storage symptoms: urgency ± urge incontinence, frequency >8/day, nocturia. May coexist with BPH. Urgency is cardinal feature. Often no outflow obstruction

Urinary Tract Infection

Acute dysuria, frequency, suprapubic pain. Systemically unwell in upper UTI. Midstream urine (MSU) dipstick + culture. Uncommon in young men — exclude STI (chlamydia, gonorrhoea)

Prostate Cancer

May be asymptomatic or cause LUTS. Hard/craggy/irregular prostate. PSA elevated or rapidly rising. Bone pain, weight loss, haematuria = advanced. Always consider in men >50 with new LUTS

Prostatitis (acute/chronic)

Perineal/pelvic pain, dysuria, fever (acute). Chronic pelvic pain syndrome: scrotal, perineal, post-ejaculatory pain. Boggy tender prostate. MSU + consider urology

Urethral Stricture

Reduced stream since trauma, instrumentation, or STI history. Young men more often. Urology for urethrogram/cystoscopy

Nocturnal Polyuria

>33% of 24hr urine produced nocturia. Rule out: cardiac failure, DM, CKD, diuretic timing, OSA. Treat underlying cause first. Desmopressin if isolated

Neurogenic Bladder

Parkinson's, MS, spinal cord disease, diabetes. Mixed storage/voiding with neurological features. Refer urology/neuro-urology

Drug causes

Anticholinergics → retention. Diuretics → frequency/nocturia. Alpha-agonists (decongestants) → retention. Alpha-blockers → incontinence. Review medication list

Up to 40% of men with LUTS have OAB as the dominant diagnosis, not BPH. Prescribing an alpha-blocker alone fails these patients and causes avoidable polypharmacy.
Prostatitis (especially chronic pelvic pain syndrome) is frequently underdiagnosed — it affects up to 15% of men and requires a different management pathway entirely.
Medication review is crucial: anticholinergic burden is a common reversible cause of voiding difficulty in older men; over-the-counter decongestants (pseudoephedrine) precipitate acute retention.
UTI in men <50 without urological risk factors should prompt STI screening — chlamydia in young men commonly presents as urethral discharge, dysuria, and frequency.

4

Diagnose

Targeted Examination — Mandatory Components

Done

A focused physical examination changes diagnosis and management in LUTS — do not skip DRE.

Abdominal exam

Suprapubic palpation/percussion — palpable bladder = retention or chronic urinary retention. Renal angle tenderness = upper UTI/pyelonephritis/hydronephrosis

Digital Rectal Exam (DRE)

Mandatory in all men with LUTS. Normal BPH: smooth, symmetrically enlarged, rubbery, median sulcus preserved. Abnormal (refer 2WW): hard, craggy, nodular, irregular, loss of sulcus, fixed. Estimate size (normal <20g)

Genitalia

Urethral discharge (STI/prostatitis), phimosis (can cause LUTS in uncircumcised men), penile pathology. Examine testes for masses (testicular cancer)

Neurological

Perianal sensation, anal tone, lower limb power/reflexes if neurogenic bladder suspected or new onset retention. Absent tone = cauda equina

Peripheral oedema

Bilateral pitting oedema → nocturnal polyuria from fluid redistribution in cardiac failure, venous insufficiency, nephrotic syndrome

BMI / waist circumference

Obesity associated with LUTS severity. Metabolic syndrome links with OAB and BPH progression (NICE CG97)

BP

Hypertension + LUTS: review diuretic/calcium-channel blocker timing. Alpha-blockers lower BP — relevant comorbidity context for prescribing

DRE is the single most important examination: prostate cancer with an abnormal DRE warrants 2WW referral regardless of PSA. PSA alone misses 20% of clinically significant cancers (NICE NG12).
A palpable bladder (chronic urinary retention) may be painless — patients sometimes present with overflow incontinence rather than retention symptoms. Missing this leads to irreversible renal damage.
Phimosis is a reversible mechanical cause of LUTS, especially in diabetic men; circumcision is curative.
Ankle oedema identifying cardiac failure redirects nocturia management from BPH treatment to heart failure optimisation — a completely different pathway.

5

Diagnose

Investigations — Baseline & Targeted Tests

Done

Investigations confirm diagnosis, establish baseline, and screen for complications. Do not over-investigate mild, uncomplicated LUTS.

Urinalysis (dipstick)

Mandatory first test. Nitrites+leucocytes → MSU for culture (exclude UTI). Blood → triggers haematuria pathway. Glucose → DM screen. Protein → renal disease

MSU culture

If dipstick positive or symptoms suggest infection. Men with true UTI need further investigation (USS kidneys, prostate) to exclude structural abnormality

PSA

Offer after informed discussion (pros/cons of testing). Do NOT check PSA if: symptomatic UTI (falsely elevated), within 4 weeks of catheterisation, within 1 week of DRE, post-ejaculation in 48h. Age-specific ranges: <50: <2.5 50–59: <3.5 60–69: <4.5 70+: <6.5 ng/mL

Renal function (U&Es)

All men with LUTS. Creatinine elevation → obstructive uropathy until proven otherwise. eGFR <45 affects drug dosing (alpha-blockers, 5-ARIs)

FBC

Anaemia may suggest renal failure (chronic obstructive uropathy) or malignancy (prostate cancer, bladder cancer)

Glucose / HbA1c

Diabetes causes osmotic polyuria, autonomic bladder neuropathy. Screen if not recent

Post-void residual (PVR)

Bladder USS after voiding. PVR >300 mL = chronic urinary retention → urology referral. Can be done in GP if bladder scanner available or refer for measurement

NOT routinely needed

Flow rate (uroflowmetry) — secondary care. Urodynamics — secondary care. Transrectal ultrasound — secondary care only. PSA velocity requires serial PSA over time

Dipstick urinalysis is the single highest-yield bedside test — it redirects to UTI pathway, haematuria pathway, or diabetic/renal screen as needed within seconds.
PSA testing requires shared decision-making: it detects prostate cancer but also generates anxiety, false positives, and overdiagnosis. NICE recommends it should be offered, not automatically done. Document the discussion.
Renal impairment with LUTS is a red flag for obstructive uropathy — same-day urology is appropriate if creatinine is significantly elevated or rising.
PVR >300 mL is an absolute indication for urology referral regardless of symptom severity — silent chronic retention causes progressive renal failure.

6

Refer

Referral Criteria — When to Refer to Urology

Done

Many men can be managed in primary care. Use these thresholds to identify those needing specialist input.

999 / A&E

Acute urinary retention (unable to void) · Septic shock · Suspected cauda equina syndrome · Obstructive renal failure (acutely rising creatinine)

Same-day urology

Painful urinary retention not yet catheterised · Significant hydronephrosis on imaging · Rapidly rising creatinine with LUTS

2WW urology

Visible painless haematuria (age ≥45) · Unexplained non-visible haematuria + raised WBC (age ≥60) · Hard, irregular, craggy prostate on DRE · PSA above age-adjusted threshold with no benign cause

Urgent routine urology

Chronic urinary retention (PVR >300 mL, painless) · Recurrent UTIs in men (≥2/year) · Suspected urethral stricture · Neurogenic bladder suspected

Routine urology

LUTS refractory to maximal primary care treatment (≥6 months, optimised alpha-blocker + 5-ARI if appropriate) · Considering surgery (TURP/HoLEP) · Failed TWOC · Uncertain diagnosis

Primary care managed

Mild LUTS (IPSS ≤7) with no red flags · Moderate LUTS (IPSS 8–19) with normal investigations, eligible for watchful waiting or pharmacotherapy · OAB without haematuria or infection

Most men with LUTS (60–70%) can be safely managed in primary care. Overreferral to urology creates unnecessary waiting, anxiety, and resource use. NICE CG97 explicitly supports primary care pharmacotherapy trials.
Recurrent UTIs in men are never normal — they imply structural abnormality (BPH causing incomplete emptying, stone, stricture, vesico-ureteric reflux) and require upper tract imaging and cystoscopy.
The 2WW threshold for haematuria is supported by NICE NG12 — even one episode of visible haematuria after age 45 meets criteria. Do not attribute it to UTI alone without completing the 2WW pathway.
Chronic painless retention (high PVR) requires surgery or long-term catheterisation to protect kidneys; primary care pharmacotherapy alone is insufficient.

7

Treat

Treatment Pathway — Drug Ladder by Symptom Phenotype

Done

Match treatment to the predominant symptom type. Voiding symptoms (BPH) and storage symptoms (OAB) require different drugs. Combination therapy is evidence-based for mixed symptoms.

Voiding symptoms dominant (BPH / outflow)

Alpha-blocker 1st line

Tamsulosin MR 400 mcg OD (post-meal) — most widely used
Alfuzosin MR 10 mg OD — less retrograde ejaculation
Doxazosin MR 4–8 mg OD — also treats hypertension
Effect in 2–4 weeks. Warn: postural hypotension, retrograde ejaculation.

Storage symptoms dominant (OAB / urgency)

Antimuscarinic or Beta-3 agonist 1st line

Solifenacin 5 mg OD (preferred anticholinergic — once daily, well tolerated)
Mirabegron 50 mg OD Prefer if cognitive concerns / frailty — avoid anticholinergic burden in elderly
Check PVR before starting — avoid if >150 mL (risk of retention)

Large prostate (>30g) or high risk progression

5-Alpha Reductase Inhibitor Add or use

Finasteride 5 mg OD — 6–12 months before full effect
Dutasteride 500 mcg OD — similar efficacy, faster onset
Reduces prostate volume by 20–30%. Reduces progression to retention/surgery by 50% (NNT ~18). Warn: reduced libido, ejaculatory dysfunction, gynaecomastia. PSA halved after 6 months — document.

Nocturia dominant (nocturnal polyuria confirmed)

Desmopressin Targeted

Desmopressin 25–100 mcg OD nocte (intranasal or oral)
Only if nocturnal polyuria confirmed on bladder diary. Check Na+ before and 3 days after starting — hyponatraemia risk in elderly. Avoid if eGFR <50, heart failure, on diuretics.

Escalation ladder (BPH-predominant)

Step 1 Lifestyle + watchful waiting — IPSS ≤7 or patient chooses. Review in 6 months. See Step 8.

Step 2 Alpha-blocker monotherapy — Tamsulosin MR 400 mcg OD. Reassess at 4–6 weeks. Continue if IPSS improves ≥3 points.

Step 3 Combination: Alpha-blocker + 5-ARI — if prostate >30g or PSA >1.5. MTOPS trial: reduces clinical progression by 67% vs monotherapy. Tamsulosin 400 mcg + Finasteride 5 mg OD (or co-formulation Combodart if available)

Step 4 Add antimuscarinic / mirabegron if persistent storage symptoms despite Step 2–3. Caution: check PVR <150 mL before adding

Step 5 Refer urology for surgical options: TURP, HoLEP, Rezum, Urolift (day-case alternatives). Surgical success ~70–80%. Consider after failed 6 months of optimised pharmacotherapy.

⚠️ Prescribing cautions

Alpha-blockers + PDE5-inhibitors (sildenafil) → profound hypotension. Tamsulosin is most selective, lowest BP drop. Antimuscarinics contraindicated if urinary retention, narrow-angle glaucoma, severe constipation. 5-ARIs contraindicated in women of childbearing potential (teratogenic — handle tablets with care)

PSA on 5-ARI

Finasteride/dutasteride halve PSA after 6–12 months. Double observed PSA to estimate true value. Document this in records to avoid missing cancer.

Acute retention post-alpha-blocker

TWOC should be done with alpha-blocker running — start tamsulosin 48h before catheter removal. Increases TWOC success to ~60%

Alpha-blockers work within 2–4 weeks, improving IPSS by ~4–6 points (NNT ~4 for meaningful improvement). They do not reduce prostate size or long-term progression.
5-ARIs (finasteride, dutasteride) take 6–12 months for full effect but prevent long-term progression to retention (NNT ~18) and reduce prostate cancer risk by 25% — this is an underused benefit.
Combination therapy (MTOPS, CombAT trials): superior to either drug alone in men with large prostates. Most cost-effective approach in high-progression-risk men.
Mirabegron over anticholinergics in older men: anticholinergic burden accumulates across polypharmacy and is associated with cognitive decline, falls, and constipation. Beta-3 agonists avoid this entirely (NICE TA290).
PDE5 inhibitors (tadalafil 5 mg OD) are licensed for LUTS/BPH in men with comorbid erectile dysfunction — a useful dual-purpose option.

8

Lifestyle

Non-Pharmacological Interventions — Evidence-Based & Often Underused

Done

Lifestyle changes are first-line for mild LUTS and an adjunct to medication for moderate-severe. Quantify the benefit to motivate patients.

Fluid management Target 1.5–2L/day. Reduce after 6pm to cut nocturia. Avoid fluid boluses. Reduces frequency and nocturia by ~20%. Bladder diary helps patients see patterns.

Caffeine reduction Coffee, tea, energy drinks → bladder irritant. Trial reducing to ≤2 cups/day. Caffeine withdrawal improves urgency in OAB — sustained benefit at 12 months (RCT evidence).

Alcohol reduction Alcohol is a diuretic and bladder irritant. Even modest reduction improves nocturia. <50g alcohol/week target aligned with cardiovascular guidance.

Bladder retraining For urgency/OAB: defer urination when urgent, gradually extend voiding intervals from 1hr → 3–4hr over 4–6 weeks. Reduces urgency episodes by ~50% (Cochrane).

Pelvic floor exercises Pelvic floor training reduces post-micturition dribble, urge incontinence, and post-prostatectomy incontinence. Refer continence nurse or physio for instruction. Sustained benefit at 1 year.

Double voiding After initial void, wait 1 minute, lean forward, void again. Reduces post-micturition dribble and incomplete emptying sensation. Simple, effective, immediate.

Weight loss Each 5kg weight loss reduces IPSS by ~2 points. Obesity increases LUTS severity via adipokine effects on prostate and bladder. Support weight management programme if BMI >30.

Physical activity Regular moderate exercise (150 min/week) reduces LUTS severity by 25% vs sedentary lifestyle. Walking reduces nocturia. Combats metabolic syndrome link with BPH progression.

Medication review Stop/switch: anticholinergics, diuretic timing (take morning, not evening), alpha-agonist decongestants (Sudafed), calcium channel blockers. Review entire medication list systematically.

Constipation treatment Chronic constipation worsens voiding and urgency via direct pressure effects. Optimise bowel habit: fibre, hydration, laxatives if needed. Often overlooked cause of worsening LUTS.

NICE CG97 explicitly recommends lifestyle interventions as first-line for all men with LUTS — they are not optional add-ons. Many mild-moderate patients respond without medication.
Bladder retraining for OAB has similar efficacy to antimuscarinics at 6 months (Cochrane systematic review 2014) — and better long-term adherence without side effects.
Evening fluid restriction reduces nocturia in the majority of patients — nocturia disrupts sleep architecture, increases falls risk, and is associated with cardiovascular mortality. It deserves specific attention as a target.
Pelvic floor rehabilitation is underreferred in men — continence nurses and physiotherapists improve outcomes for post-micturition dribble and urge incontinence significantly.
The medication review step can be curative: stopping an anticholinergic or switching diuretic timing to morning can resolve LUTS within days without any new prescription.

9

Safety

Follow-Up, Monitoring & Safety-Netting

Done

Structured follow-up ensures treatment response is captured, complications identified early, and PSA surveillance maintained.

4–6 weeks

Review alpha-blocker: IPSS, symptom response, BP (postural hypotension), side effects (retrograde ejaculation, dizziness). Repeat dipstick if UTI treated. Review bladder diary if commenced.

3 months

Repeat IPSS — document change. If IPSS improved ≥3 points: continue and review at 6 months. If no response: review adherence, diagnosis, consider 5-ARI addition or referral

6 months

Repeat U&Es (especially if starting 5-ARI or OAB treatment). Check PSA if on 5-ARI (remember to document that true value = measured PSA × 2 after 6 months of treatment)

Annual review

Repeat IPSS annually. Review prostate health: PSA trend, DRE. Recheck renal function. Consider step-down if mild LUTS sustained for 12 months. Ask about sexual function (treatment side effects)

Watchful waiting monitoring

If IPSS ≤7 and watchful waiting chosen: review at 12 months. Trigger re-assessment if IPSS worsens by ≥3 points or new symptoms emerge

Safety-net 999

Sudden inability to pass urine (acute retention) · Severe haematuria with clots · Collapse / fever / rigors (urosepsis) · New saddle anaesthesia, bilateral leg weakness (cauda equina)

Safety-net same-day GP

Frank haematuria (new or recurrent) · Unable to tolerate pain / urinary discomfort · Fever / unwell suggestive of UTI / prostatitis · Worsening LUTS with systemic symptoms (weight loss, bone pain)

PSA surveillance

Men on watchful waiting or treated BPH: annual PSA if not already enrolled in surveillance. Document PSA trend. PSA doubling time <2 years = urgent urology referral. Rising PSA on 5-ARI (even when 'normal') = urgent referral

Medication safety

Antimuscarinics: review annually for anticholinergic burden (dementia link); switch to mirabegron in men >65 if still on antimuscarinics. 5-ARIs: sexual side effects often improve but discontinuation rate high — address at 6 months

Patient information

Provide LUTS / BPH patient leaflet (PCUK / NHS). Encourage prostate health discussions with partners. Register with Prostate Cancer UK if worried about cancer risk. Confirm they know when to return urgently.

PSA monitoring in men on 5-ARIs is a key patient safety issue: halved PSA values can falsely reassure — rising PSA on treatment (even within 'normal' range) is a red flag for cancer. NICE CG97 and CKS emphasise documenting this adjustment.
Annual anticholinergic burden review is increasingly important: anticholinergics for OAB are associated with accelerated cognitive decline (HR 1.2–1.4 in longitudinal studies). STOPP/START criteria recommend deprescribing in men over 65.
Acute retention has a 25% recurrence rate within 1 year of TWOC — men must know this is an emergency requiring immediate A&E assessment.
PSA velocity (doubling time <2 years) is more sensitive for clinically significant prostate cancer than absolute value — this requires serial measurement and trend monitoring, ideally in the same GP system for continuity.
Structured IPSS tracking at each visit allows objective assessment — a perception of stability can mask a gradual decline. The IPSS is the outcome measure for NICE quality standard QS45.